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Effects of sevelamer and calcium on coronary artery calcifica-
tion in patients to new hemodialysis.
Background. Hemodialysis patients are at increased risk for
progressive coronary artery calcification; however, the devel-
opment and progression of this disease process in patients new
to hemodialysis is unknown.
Method. One hundred and twenty-nine patients new to
hemodialysis were randomized to receive calcium containing
phosphate binders or the noncalcium phosphate binder seve-
lamer hydrochloride. Subjects underwent electron beam com-
puted tomography scanning (EBCT) at entry into the study and
again at 6, 12, and 18 months.
Results. One hundred and nine patients underwent baseline
and at least one additional assessment of coronary calcifica-
tion. At baseline, 37% of sevelamer treated and 31% of calcium
treated patients had no evidence of coronary calcification. No
subject with a zero coronary artery calcium score (CACS) at
baseline progressed to a CACS >30 over 18 months. Subjects
with a CACS > 30 at baseline showed progressive increases in
CACS in both treatment arms (P < 0.05 for each time point
in both groups). Subjects treated with calcium containing phos-
phate binders showed more rapid and more severe increases
in CACS when compared with those receiving sevelamer hy-
drochloride (P = 0.056 at 12 months, P = 0.01 at 18 months).
Conclusion. New hemodialysis patients with no evidence of
coronary calcification showed little evidence of disease develop-
ment over 18 months independent of phosphate binder therapy.
However, subjects with evidence of at least mild coronary calci-
fication had significant progression at 6, 12, and 18 months. Use
of calcium containing phosphate binders resulted in more rapid
progression of coronary calcification than did use of sevelamer
hydrochloride.
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Patients with chronic kidney disease on dialysis ex-
hibit a greater burden of vascular calcification (VC)
than age- and sex-matched individuals without kidney
disease [1]. Randomly chosen patients on hemodial-
ysis were reported to have coronary artery calcium
scores (CACS) evaluated by electron beam computed
tomography (EBCT) over 5-fold higher than age- and
sex-matched individuals with established coronary artery
disease but normal kidney function [1]. Recognition that
increasing CACS have been associated with an increase in
cardiovascular events in the general population, together
with the consistent observation of a 10- to 100-fold higher
cardiovascular event rate in the dialysis population, has
led to a renewed interest in the natural history and patho-
genesis of vascular calcification in patients with end-stage
renal disease (ESRD) [2, 3] Indeed, the presence and ex-
tent of VC has been shown to be a significant predictor of
cardiovascular morbidity and mortality in patients with
ESRD [4] and, thus, therapeutic interventions that alter
the development or progression of VC are likely to be of
benefit. Previous evaluations of coronary artery calcifi-
cation in patients on hemodialysis have been conducted
in prevalent populations with an average time on dialy-
sis between 39 and 65 months [5, 6]. In these prevalent
populations, coronary artery calcification was identified
in 83% to 89% of patients and was associated with the de-
gree of calcium and phosphorus control, suppression of
intact parathyroid hormone (iPTH) below recommended
target values, and with the use of calcium containing phos-
phate binders.
This study was conducted to specifically assess the de-
gree of coronary artery calcification in a cohort of patients
new to hemodialysis, and to examine the role of calcium
containing phosphate binders and sevelamer hydrochlo-
ride, a noncalcium containing phosphate binder on the
development and progression of VC.
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METHODS
Subjects
Adult (>18 years) patients new to hemodialysis were
enrolled at 5 participating dialysis centers in the United
States. Exclusion criteria included a prior history of dial-
ysis, kidney transplant, coronary artery bypass surgery,
weight greater than 300 pounds (due to the weight limit
of the cradle of the EBCT machine), or current atrial fib-
rillation or atrial flutter. The latter was done to ensure
minimum motion artifact induced by arrhythmia and to
maximize image quality on EBCT scanning. Enrollment
began in September 2000 and continued through Decem-
ber 2002.
Written informed consent was obtained from all sub-
jects before study related procedures were performed
and after approval from each institutional Investiga-
tional/Ethical Review Board, and in adherence with the
Declaration of Helsinki guidelines regarding ethical prin-
ciples for medical research involving human subjects.
Study design
Patients were stratified by diabetes and randomized
in a 1:1 fashion to receive either open label sevelamer or
calcium containing phosphate binders. Randomization to
treatment was computer generated in blocks of 10 and
assigned by the coordinating center using concealed en-
velopes. Electron beam computed tomography was per-
formed at baseline, and repeated again at 6, 12, and
18 months.
Investigators were instructed to control parameters
of mineral metabolism [calcium, phosphorus, calcium ×
phosphate product (Ca × P), and intact parathyroid hor-
mone (iPTH)], and dyslipidemia per their clinic routine.
No study specific management protocols were provided.
This study predated publication of the National Kidney
Foundation Kidney Disease Outcomes Quality Initia-
tive (NKF K/DOQI) clinical practice guidelines for bone
disease and metabolism in chronic kidney disease, al-
though clinical practice typically included target values of
<10.2 mg/dL for serum calcium, <6.5 mg/dL for serum
phosphorus, <65 mg2/dL2 for Ca × P, and an iPTH be-
tween 150 and 300 pg/mL. Investigators were free to
alter phosphate binder dose and, within the calcium treat-
ment arm, to alternate between various types of calcium
containing phosphate binders at their discretion. Patients
randomized to sevelamer were allowed to take calcium as
a nightly supplement at the discretion of the investigator.
The dialysate calcium concentration was maintained at
2.5 mEq/L throughout the study period. No estimate of
patient adherence (pill count) was performed, and no pa-
tients received calcimimetic agents during the course of
the clinical trial. Investigators and clinicians were blinded
to the EBCT results. Baseline medical conditions were
assessed by chart review and were based on clinical diag-
noses.
Laboratory measurements
Routine biochemical laboratory measurements were
obtained at baseline and at monthly intervals. Measure-
ments were performed by the facilities’ usual laborato-
ries (DaVita Laboratories, Gambro Laboratories, RCG
Laboratories, University of California San Diego Labo-
ratory, Tulane University Hospital Laboratories). Mea-
surement of intact PTH was performed using the Nichols
second generation immunoradiometric intact PTH as-
say (Nichols, Inc., San Clemente, CA, USA). Additional
parathyroid hormone testing was performed measuring
1–84 PTH (Scantibodies, Inc., Santee, CA, USA). C-
reactive protein (CRP) and nonfasting lipid profiles were
shipped frozen on ice to Medtox Laboratories (St. Paul,
MN, USA) at baseline, 6, 12, and 18 months. High sensi-
tivity CRP was measured using an immunoturbidimetric
assay (normal <5 mg/L). Low-density lipoprotein (LDL)
cholesterol was calculated using the Friedewald equation
on nonfasting predialysis blood samples [7].
Imaging procedure
Electron beam computed tomography (EBCT) scans
were performed using a C-150 scanner (GE-Imatron, San
Francisco, CA, USA). Imaging was performed as previ-
ously described with 100-msec scanning time and a sin-
gle slice thickness of 3 mm [8]. Forty to 60 slices were
obtained at each scanning session, mostly during a sin-
gle breath holding period. Imaging, triggered at 60% of
the R-R interval on the electrocardiogram, began 0.5 cm
above the aortic arch and extended to the level of the di-
aphragm. All areas of calcification with a minimal density
of 130 Hounsfield Units (HU) within the borders of the
coronary arteries were computed. A calcified plaque was
considered present if at least three contiguous pixels with
a density of 130 HU or greater were detected. All images
were reviewed on a NetraMD workstation (ScImage, Los
Altos, CA, USA). Scans were considered of acceptable
research quality only if the images were free from motion
or metal artifacts. Scans were read by a single experienced
investigator (P.R.) who was blinded to all other patient
data. A calcium score for each area of interest was cal-
culated as originally described by Agatston et al [9]. This
scoring method incorporates the density and volume of a
calcified plaque; therefore, a score increase may be due to
either plaque enlargement or increased density or both.
The reverse would be true for a score decrease. Total cal-
cium scores were calculated as the sum of all individual
coronary artery scores. The published median interscan
CACS variability is 8% to 10% for the Agatston score
[10–12]. For descriptive purposes, subjects were classified
as having no coronary calcification (absolute total CACS
of zero) versus nonzero.
Block et al: Sevelamer and calcium in new hemodialysis patients 1817
Statistical analysis
The primary aims of this study were to assess the de-
gree of coronary artery calcification in a cohort of pa-
tients new to hemodialysis, and to compare the impact of
sevelamer versus calcium containing phosphate binders
on the development and progression of coronary artery
calcification. We estimated that 50 patients in each arm
would provide 80% power to detect a difference of 500
in absolute CACS at 12 months between the two groups,
with significance defined as a P value less than or equal
to 0.05.
Pretreatment and end of study characteristics were
compared between the sevelamer and calcium groups us-
ing the Fisher exact test for categorical variables and the
Wilcoxon rank sum test for continuous variables. Missing
laboratory variables and CACS were not imputed. Com-
parisons of longitudinal changes in CACS were made
only between subjects who remained in the study at each
time a measurement was repeated. Serial assessments of
change from baseline in calcium scores were compared
within treatment groups using the Wilcoxon signed rank
test and compared between treatment groups using the
Wilcoxon rank sum test. Spearman correlation was used
to assess the relationship between progression of CACS
and selected covariables, including hs-CRP, prescribed
doses of elemental calcium, and dose of vitamin D.
Data for CACS were not normally distributed, thus
medians were considered the more accurate measure of
central tendency. Evaluation of the change in calcification
was done in several ways depending on the presence or
absence of baseline coronary artery calcification. Because
of the potential magnification of percentage change over
time for small baseline scores and the inability to assess
percent change among those with zero baseline CACS,
we calculated absolute change in calcium scores for all
patients independent of the baseline score, but we calcu-
lated a relative score change only in those with a baseline
score >30. A calcium score >30 has been reported to
be highly reproducible (8–10% interscan variability) and
was therefore used as a threshold to calculate percent-
age change in calcium score on sequential EBCT scans
[10]. To clarify the latter concept one should consider that
an increase of 10 points represents a 100% increase for a
baseline score of 10, but only a 30% increase for a baseline
calcium score of 30. It has been suggested that a coronary
artery score change (either increase or decrease) greater
than 15% may be considered evidence of true change as
opposed to scoring variability; therefore, progression and
regression were defined as a change of at least 15% from
baseline [10].
All probability values are two-tailed. P values ≤ 0.05
were considered statistically significant. Analyses were
conducted using SAS 8.2 (Cary, NC, USA) and GraphPad
Prism 3.0 (San Diego, CA, USA).
RESULTS
Subjects
Patient disposition is shown by treatment group in
Figure 1. Eighty-two percent of patients underwent
baseline EBCT scanning within 120 days of initiating
hemodialysis, with 97% undergoing baseline scanning
within 180 days. The majority of screen failures were
due to subjects declining to participate. Reasons for not
reaching the 18-month EBCT scan were similar between
treatment groups. Table 1 shows baseline demographics
and medical history of the randomized patients who un-
derwent a baseline and at least one subsequent EBCT
examination. Significantly more patients randomized to
sevelamer had a prior history of atherosclerotic vascular
disease (previous myocardial infarction, history of coro-
nary angioplasty and/or stent placement, angina pectoris,
evidence of coronary atherosclerotic disease, stroke, tran-
sient ischemic attack, claudication, lower extremity inter-
ventions for atherosclerotic disease, or aortic aneurysm)
(P < 0.04).
Table 2 shows the clinical laboratory values at baseline
and during follow-up, as well as the relevant concomitant
medication use of the patients randomized to the two
treatment groups.
Of the 55 patients in the calcium arm, 38 received cal-
cium carbonate only, 3 received calcium acetate only, and
14 received both medications during the 18-month study
period. There were no significant differences at baseline
or at the end of study in the use of HMG Co-A reduc-
tase inhibitors, ACE inhibitors, beta blockers, or vitamin
D sterols. The proportion of patients using vitamin D
increased slightly but not significantly in the sevelamer
arm, while the proportion of subjects on vitamin D was
unchanged in the calcium arm. In subjects receiving vi-
tamin D, the average paricalcitol equivalent (1 lg cal-
citriol = 3 lg paricalcitol) doses of vitamin D used were
10.2 lg/week (sevelamer) and 10.1 lg/week (calcium).
The average sevelamer dose was 8 g/day (∼10 pills), and
the average dose of elemental calcium was 2.3 g/day. Two
subjects in the sevelamer group were given nightly cal-
cium supplementation.
Biochemical end points
Relevant biochemical end points are shown in Figure
2 and Table 2. Patients in both treatment arms demon-
strated similar control of serum phosphorus and Ca ×
P. However, subjects treated with sevelamer had signifi-
cantly lower mean corrected calcium (P < 0.0001), higher
iPTH (P = 0.05), higher PTH (1–84) (P = 0.03), lower
total cholesterol (P = .003), and lower LDL-cholesterol
(P = 0.0003). While there were no differences in episodes
of hyperphosphatemia between treatment groups, pa-
tients assigned to calcium were significantly more likely
to experience episodes of moderate hypercalcemia
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Declined/screen failures (N=237) Randomized (N=148)
Calcium (N=75) Sevelamer (N=73)
Baseline EBCT (N=67) Baseline EBCT (N=62)
Adverse Event (N=1)
Transplanted (N=3)
Death (N=1)
Other (N=4)
Lost to follow up (N=1)
Transferred to PD (N=2)
Available for analysis (N=55)
(at least 1 post baseline EBCT)
Available for analysis (N=54)
(at least 1 post baseline EBCT)
Adverse event (N=1)
Transplanted (N=2)
Death (N=1)
Other (N=2)
Transferred to PD (N=2)
Fig. 1. Patient disposition.
(>10.2 mg/dL) (calcium 54% vs. sevelamer 22%, P =
<0.0001), severe hypercalcemia (>11.0 mg/dL) (calcium
24% vs. sevelamer 5%, P = <0.02), episodes of rela-
tively low iPTH (intact PTH <150 pg/mL) (calcium 29%
vs. sevelamer 18%, P < 0.0001), or low iPTH (intact
PTH < 100 pg/mL) (calcium 20% vs. sevelamer 7%,
P < 0.0001). Similar results were obtained with the PTH
(1–84) parathyroid hormone assay (data not shown). Hy-
percalcemia (at least 1 serum calcium >10.2 mg/dL) was
associated with a mean iPTH of 366 pg/mL in subjects
given sevelamer versus a mean iPTH of 255 in subjects
receiving calcium (P = 0.05). Finally, hs-CRP increased
in both treatment arms (sevelamer P = 0.05, calcium P =
0.06), although there was no difference in the degree of
change between treatment groups.
Cardiovascular calcification
At baseline, 37% of sevelamer treated subjects and
31% of calcium treated subjects had no detectable coro-
nary artery calcium. The mean and median baseline
CACS were not different between treatment groups (P =
0.55). Twenty-seven percent of diabetic subjects had a
zero CACS in contrast with 43% of nondiabetic sub-
jects (P = 0.10). Demographic characteristics of subjects
with no evidence of baseline CACS are shown in Table 1.
Subjects with a nonzero CACS were older (P < 0.0001)
and had significantly higher hs-CRP (P = 0.04), while all
other baseline laboratory values were similar between
the treatment groups. There was no significant correla-
tion between days from starting dialysis to first EBCT and
baseline CACS. No patient with a zero CACS at baseline
progressed to a CACS >30.
Figure 3 and Table 3 show the median absolute CACS
and the relative increase in CACS at various time
points over the 18 months of follow-up for all subjects.
Both cohorts experienced significant within-group in-
creases in CACS at each time point. However, the ex-
tent of progression among subjects receiving calcium was
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Table 1. Baseline demographic and clinical characteristics of study participants
Sevelamer Calcium Baseline CACS = 0 Baseline CACS >0
(N = 54) (N = 55) P valuec (N = 37) (N = 72) P valuec
Age years mean ± SD 57 ± 15 59 ± 15 n/s 45 ± 12 64 ± 11 < 0.0001
Sex% male 59% 67% n/s 65% 63% n/s
Race
White 43% 40% n/s 35% 44% n/s
Black 26% 36% n/s 24% 35% n/s
Diabetes 63% 56% n/s 47% 65% n/s
Hypertension 96% 98% n/s 97% 97% n/s
Prior myocardial infarction 15% 7% n/s 3% 15% .06
Congestive heart failure 13% 19% n/s 8% 19% n/s
Coronary artery diseasea 28% 18% n/s 19% 25% n/s
ASCVDb 41% 22% < 0.04 24% 35% n/s
Hypercholesterolemia 31% 35% n/s 22% 39% n/s
Primary cause of ESRD
Diabetes 56% 51% n/s 46% 57% n/s
Hypertension 19% 20% n/s 14% 22% n/s
Glomerulonephritis 9% 5% n/s 14% 4% n/s
Other 15% 24% n/s
Time from 1st dialysis to 1st EBCT days 86 ± 42 89 ± 43 n/s
Baseline demographic and clinical characteristics of patients with a baseline and at least 1 follow-up EBCT by treatment group.
aCoronary artery disease includes previous MI, prior coronary artery angioplasty and/or stent placement, angina pectoris, and objective evidence of coronary
atherosclerotic disease.
bASCVD includes previous MI, history of coronary artery angioplasty and/or stent placement, angina pectoris, evidence of coronary atherosclerotic disease, stroke,
transient ischemic attacks, claudication, lower extremity interventions for atherosclerosis, aortic aneurysm.
cFisher exact test for categorical factors and Wilcoxon rank-sum test for continuous factors.
Table 2. Characteristics of study participants
Sevelamer (N = 54) Calcium (N = 55)
Variable (mean ± SD) Baseline On treatment average Baseline On treatment average
Albumin g/dL 3.5 ± 0.6 3.8 ± 0.3 3.7 ± 0.5 3.8 ± 0.4
Calcium corrected mg/dL 9.3 ± 1.0 9.1 ± 0.5a 9.3 ± 0.8 9.6 ± 0.5a
Phosphorus mg/dL 5.2 ± 1.6 5.2 ±.9 5.4 ± 1.4 5.1 ± 0.8
Ca × P mg2/dL2 48 ± 14 47 ± 7 49 ± 13 49 ± 8
Intact PTH pg/dL 293 ± 323 298 ± 152a 319 ± 383 243 ± 136a
Total cholesterol 157 ± 49 134 ± 52a 153 ± 39 160 ± 32a
LDL cholesterol mg/dL 72 ± 36 60 ± 34a 72 ± 30 81 ± 26a
Triglycerides mg/dL 183 ± 108 171 ± 108 188 ± 108 191 ± 106
C-reactive protein mg/L 6.7 ± 6.4 9.1 ± 9.7 7.6 ± 7.9 10.5 ± 10.3
HMG Co-A reductase use% 36% 42% 24% 35%
ACE inhibitor use% 49% 59% 54% 57%
Beta blocker use% 40% 45% 48% 59%
Vitamin D use% 55% 68% 52% 52%
Baseline and post-baseline laboratory values and medication use for study participants. Laboratory values represent the mean of all available laboratory tests during
the study. Missing values were not imputed. Medication use was defined as positive if study participants were on the medication for ≥50% of their study duration or
greater than 6 months.
aP ≤ 0.05 for between group comparisons.
progressively larger over time compared with sevelamer-
treated subjects. The median increase in CACS at 18
months was 11-fold greater in the calcium treated group
compared to the sevelamer-treated group (127 points in-
crease vs. 11 points increase, P = 0.01). The median in-
crease in CACS in subjects censored after 6 and 12 months
was 9.0 and 0.0, respectively, in subjects receiving seve-
lamer and 4.0 and 0.0, respectively, in subjects receiving
calcium.
Analysis of absolute and percentage change in calcifi-
cation score in subjects with baseline CACS >30 showed
a similar trend with earlier and more severe progression
of coronary calcification in calcium treated subjects (P =
0.0564 for intergroup percent change at 12 months, P =
0.0572 at 18 months) (Table 4).
Figure 4 shows the proportion of subjects with baseline
CACS >30 experiencing actual progression (greater than
15% increase) versus no progression of CACS. Subjects
treated with sevelamer were significantly more likely to
experience stabilization or regression in CACS at the 12-
month (P = 0.003) and 18-month (P = 0.01) time points.
At 18 months, diabetic subjects treated with calcium
(N = 25) experienced significantly larger increases in
CACS (median increase 177) compared to diabetic sub-
jects given sevelamer (N = 27, median increase 27) (P =
0.05).
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Fig. 2. Average monthly serum phosphorus by binder type.
Analyses done using the entire cohort showed no sig-
nificant relationship between C-reactive protein, dose of
elemental calcium prescribed, or average vitamin D dose
and progressive changes in CACS. Similarly, there were
no significant differences in change in CACS between pa-
tients using HMG Co-A reductase inhibitors or vitamin
D and patients not using these drugs.
Correlation analysis using demographic and laboratory
variables showed that age (r = .38, P < 0.0001), baseline
PTH (r = .24, P = 0.01), mean LDL cholesterol (r = .26,
P = 0.007), mean total cholesterol (r = .20, P = 0.03), and
baseline CACS (r = .53, P < 0.0001) were significantly
correlated with change in total CACS among the entire
cohort. Mean on-treatment PTH was not correlated with
change in CACS.
DISCUSSION
This study examined the effects of alternative phos-
phate binder strategies on coronary artery calcification in
patients new to hemodialysis over an 18-month follow-up
period. This study is novel in that it presents three impor-
tant findings. First, a substantially greater proportion of
patients new to dialysis had no visible coronary calcifi-
cation compared to previous reports of subjects under-
going chronic hemodialysis [5]. This finding is consistent
with the recent report by Russo et al describing an even
lower prevalence of calcification in patients with stage 4
chronic kidney disease [13]. Second, subjects with no ev-
idence of coronary artery calcification upon initiation of
dialysis showed little evidence of coronary artery calci-
fication development during follow-up. Third, while all
subjects with evidence of baseline coronary calcification
showed progression over time, patients randomized to
calcium containing phosphate binders experienced signif-
icantly more rapid and more severe progression of disease
than did those randomized to sevelamer. Despite overall
good control of the parameters of mineral metabolism,
nearly all patients (93%) with baseline coronary calcifica-
tion randomized to calcium containing phosphate binders
demonstrated a true increase in CACS (>15%) at the
end of 18 months, while 40% of patients randomized to
sevelamer showed no progression. This degree of pro-
gressive coronary calcification should be considered wor-
risome. In a recent publication, progression of this degree
in nonuremic individuals was associated with an 11- to 17-
fold increase in the risk of myocardial infarction during
follow-up [14, 15]. Similar data remain lacking for pa-
tients with CKD; however, these data constitute a warn-
ing that should not be dismissed.
During the 18-month observation period no subject
with a zero baseline CACS developed meaningful coro-
nary calcification. This suggests that a significant percent-
age of patients starting hemodialysis remain noncalcified
despite the uremic environment. Whether this noncalci-
fied state persists or is lost as time on dialysis increases
is unknown. Cross-sectional data, however, suggest that
the proportion of patients on dialysis who have no vascu-
lar or valvular calcification diminishes over time. While
in the current study we found 36% of the patients (26%
of diabetics) with a zero CACS, other reports have de-
scribed absence of coronary calcium in 17% of subjects
on hemodialysis for an average of 39 months and 11% of
subjects on hemodialysis for an average of 65 months [5,
6]. Potential explanations for these differences include
study cohort demographic differences, increases in the
number of subjects accumulating coronary artery calcium
over time, or an increased mortality or transplantation
rate in patients with zero scores.
This clinical trial does not explain the mechanisms
whereby treatment with calcium containing phosphate
binders increases coronary artery calcification. The most
obvious explanation would implicate overexposure to ex-
ogenous calcium as the culprit; however, patients with
no or minimal calcification at baseline did not develop
or progress despite “calcium loading.” Furthermore, we
found no relationship between the amount of exoge-
nous calcium administered (the actual calcium load) and
the severity of progressive disease. Previous investigators
have shown significant progression in vascular calcifica-
tion with doses of elemental calcium as small as 1.1 g/day
[5].
It is has been suggested that the vascular response to
exogenous calcium administration depends in part upon
the ability of the skeleton to buffer calcium [16]. Thus, in
the setting of impaired bone buffering, even small calcium
“loads” are poorly tolerated and may lead to progressive
increases in coronary artery calcium. A clinical marker
of impaired bone buffering capacity is the occurrence of
overt hypercalcemia. We find significant differences in
the occurrence of this laboratory abnormality in patients
treated with calcium when compared to those treated
with the noncalcium phosphate binder, sevelamer. Al-
though patients in the calcium group were no more likely
to experience hyperphosphatemia, they were far more
likely to develop episodic hypercalcemia with nearly 50%
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Table 3. Absolute increase in coronary artery calcium scores in all subjects
Wilcoxon rank-sum
Sevelamer Calcium test (P value)
Baseline 0.555
N 54 55
Mean ± SD 648 ± 1499 667 ± 1248
Median 68 96
6-month increase from baseline 0.344
N 51 53
Mean ± SD 16 ± 286 48 ± 452
Median 0 13
Wilcoxon signed rank test (P value) 0.0269 0.0125
12-month increase from baseline 0.056
N 45 47
Mean ± SD 87 ± 324 169 ± 311
Median 0 42
Wilcoxon signed rank test (P value) 0.0130 <0.0001
18-month increase from baseline 0.015
N 40 45
Mean ± SD 138 ± 412 338 ± 707
Median 11 127
Wilcoxon signed rank test (P value) 0.0011 <0.0001
Absolute increase in coronary artery calcium score by treatment group for all subjects. At each time-point for each comparison, treatment cohorts are compared to
their own baseline values for determining absolute change.
having at least one episode of a serum calcium >10.2
mg/dL. Recent epidemiologic evidence supports the con-
cept that there is an enhanced mortality risk associated
with the combination of low bone turnover, high serum
calcium, and high serum phosphorus [17]. There is also
now clinical evidence that subjects with histologic evi-
dence of low bone turnover have significantly greater ev-
idence of vascular calcification [16]. Thus, exposure to
even low dose exogenous calcium in patients with low
bone turnover may lead to transient increases in serum
calcium and, ultimately, progression of vascular calcifica-
tion. It is biologically plausible that the relation between
bone turnover and serum calcium underlies the recent
report of an association between higher adjusted serum
calcium and mortality in patients on hemodialysis [18].
Despite these observational relationships, we were not
able to show a significant association between the occur-
rence of isolated instances of hypercalcemia and change
in total CACS.
Our data extend previous observations regarding vas-
cular calcification in patients with ESRD. Importantly,
the issue of dialysis “vintage” has been isolated in this
clinical trial of incident dialysis patients. While there can
be little doubt that time on dialysis is associated with pro-
gressive increases in vascular calcification, the results of
this study demonstrate that rapid and marked progres-
sion of coronary artery calcification can occur within 6
months of starting hemodialysis and is linked to the phos-
phate binding therapy selected. Furthermore, we have
demonstrated that a substantial proportion of subjects
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Table 4. Absolute and relative increase in coronary artery calcium scores in patients with baseline coronary artery calcium score >30
Wilcoxon rank-sum
Sevelamer Calcium test (P value)
Baseline 0.5529
N 29 35
Mean ± SD 1205 ± 1886 1047 ± 1437
Median 470 477
6-month
N 26 35
Absolute increase 0.7100
Mean ± SD 28 ± 404 77 ± 557
Median 43 68
Wilcoxon signed rank test (P value) 0.0823 0.0284
Percentage increase 0.2971
Mean ± SD 17 ± 35 24 ± 50
Median 10 26
12-month
N 25 29
Absolute increase 0.1451
Mean ± SD 153 ± 427 271 ± 362
Median 72 142
Wilcoxon signed rank test (P value) 0.0316 <0.0001
Percentage increase 0.0564
Mean ± SD 33 ± 51 75 ± 102
Median 13 41
18-month
N 20 29
Absolute increase 0.0572
Mean ± SD 260 ± 562 520 ± 830
Median 156 347
Wilcoxon signed rank test (P value) 0.0094 <0.0001
Percentage increase 0.0599
Mean ± SD 43 ± 58 109 ± 144
Median 38 52
Absolute and percent increase in coronary artery calcium score in patients with baseline coronary artery calcium score ≥30. At each time-point for each comparison,
treatment cohorts are compared to their own baseline values for determining absolute and relative change.
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Fig. 4. Proportion of subjects with progression or no progression of coronary artery calcium scores among subjects with baseline coronary artery
scores >30.
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remains without significant coronary artery calcification
after 18 months, suggesting that factors beyond mineral
metabolism must be considered.
As expected, sevelamer use was associated with sig-
nificant decreases in LDL cholesterol; however, HMG
Co-A reductase inhibitor use was similar in both treat-
ment groups, and achieved LDL levels were excellent
in both treatment arms. Similar to observations in sub-
jects without chronic kidney disease, there were signif-
icant correlations between on treatment average LDL
and total cholesterol and change in CACS, suggesting that
lipid lowering therapy may favorably impact progressive
coronary artery calcification. However, due to the non-
normality of the CACS results, we were unable to per-
form a statistically valid multivariable linear regression
to examine the independent role of lipid lowering.
Limitations
The primary limitation of this study was the small num-
ber of patients studied, a limitation further enhanced, in
retrospect, by the lack of development of coronary artery
calcium in patients with a zero CACS at entry. Nonethe-
less, this limitation should increase the likelihood of find-
ing no differences between treatment groups in progres-
sion of CACS at end of study and further underscores the
significance of our results. This study cannot address the
important issue of whether calcification is occurring in
association with intimal plaque or in the smooth muscle
medial layer. We did not measure serum levels of po-
tential inhibitors of calcification such as fetuin-A, which
might have helped explain some of the results.
An aspect of this study that could be seen both as a lim-
itation and strength is that it was conducted in the course
of usual patient care and, therefore, represents “real life”
medical care. Investigators were asked to achieve control
of mineral metabolism but were not mandated to fol-
low any standardized treatment protocol. This resulted
in good control of all laboratory parameters but at the
expense of increased calcium exposure in the calcium
treatment group. This underscores the difficult challenge
faced when clinicians try to treat all aspects of mineral
metabolism concurrently with the available tools.
CONCLUSION
We find that patients new to hemodialysis with ev-
idence of at least mild coronary artery calcification at
baseline showed a significant increase in CACS within 6
months of starting dialysis, despite control of laboratory
parameters of mineral metabolism. The use of calcium
containing phosphate binders markedly accelerated both
the time course and severity of this process. Patients with
no coronary artery calcium at entry into dialysis showed
little development of disease over an 18-month obser-
vation period, regardless of phosphate binder therapy.
While the mechanisms accounting for these results cannot
be ascertained, it appears that sevelamer use attenuates
the risk of progressive coronary artery calcification in pa-
tients with ESRD and may have to be considered early
in the treatment of new dialysis patients. Additionally,
these data suggest that routine screening of new dialysis
patients for the presence of vascular calcification may al-
low early identification of subjects at risk for progressive
disease who would benefit from noncalcium containing
phosphate binders, as suggested by the K/DOQI guide-
lines for bone and mineral metabolism [19].
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